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Abstract
This viewpoint highlights major, partly controversial concepts about the pathogenesis 
of pemphigus. The monopathogenic theory explains intra- epidermal blistering through 
the “desmoglein (Dsg) compensation” hypothesis, according to which an antibody- 
dependent disabling of Dsg 1- and/or Dsg 3- mediated cell–cell attachments of 
keratinocytes (KCs) is sufficient to disrupt epidermal integrity and cause blistering. The 
multipathogenic theory explains intra- epidermal blistering through the “multiple hit” 
hypothesis stating that a simultaneous and synchronized inactivation of the physiolog-
ical mechanisms regulating and/or mediating intercellular adhesion of KCs is neces-
sary to disrupt epidermal integrity. The major premise for a multipathogenic theory is 
that a single type of autoantibody induces only reversible changes, so that affected 
KCs can recover due to a self- repair. The damage, however, becomes irreversible 
when the salvage pathway and/or other cell functions are altered by a partnering 
autoantibody and/or other pathogenic factors. Future studies are needed to (i) cor-
roborate these findings, (ii) characterize in detail patient populations with non- Dsg- 
specific autoantibodies, and (iii) determine the extent of the contribution of non- Dsg 
antibodies in disease pathophysiology.
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1  | INTRODUCTION
Pemphigus vulgaris (PV) is a potentially lethal mucocutaneous blister-
ing disease characterized by IgG autoantibodies (PVIgG) binding to 
keratinocytes (KCs). Patients with PV develop cell–cell detachment 
(acantholysis), blisters and non- healing erosions due to suprabasal split 
within the epidermis. Identification of the nature of proteins target-
ed by PV autoimmunity and elucidation of molecular mechanism of 
acantholysis have been a subject of intensive research during the last 
three decades. While several hypotheses were put forward to explain 
the mechanism of pemphigus acantholysis, the field has been domi-
nated by studies focused on desmoglein (Dsg) 1 and 3, the results of 
which gave rise to a strong believe that anti- Dsg antibodies have the 
primary role. Indeed, as these antibodies are found in the vast majority 
of pemphigus patients, they may play a pivotal role in disease patho-
physiology. The fact that anti- Dsg antibodies are pathogenic, however, 
does not mean that antibodies to other self- antigens might not also 
be pathogenic. If non- Dsg antibodies alone were responsible for some 
cases of PV, one would expect to see a certain number of cases of 
acute PV with antikeratinocyte antibodies detectable by direct and/
or indirect immunofluorescence but negative by Dsg 1/3 ELISA. This 
was indeed the case in a number of studies. Different authors reported 
5,1 6,2 9,3 10,4 17,5 196 and even 33%7 of patients with PV lacking 
both anti- Dsg 1 and anti- Dsg 3 antibodies by ELISA. Additionally, the 
monopathogenic theory of pemphigus has been challenged by reports 
showing the presence of various species non- Dsg antibodies in PV 
sera and activation of multiple signalling pathways in KCs exposed to 
PVIgG, strongly suggesting that non- Dsg pathways are also involved.
In this viewpoint article, we discuss the major controversies about 
the pathogenesis of pemphigus summarized in Table 1, and review 
“pros and cons” of the monopathogenic and multipathogenic explana-
tions of disease pathophysiology.
2  | THE MONOPATHOGENIC THEORY OF 
PEMPHIGUS PATHOPHYSIOLOGY
The monopathogenic theory of pemphigus pathophysiology explains 
intra- epidermal blistering through the “Dsg compensation” hypoth-
esis. According to this hypothesis, Dsg 1 and 3 antibody profiles and 
the normal epidermal distributions of Dsg 1 and 3 determine the sites 
of blister formation within epidermis in PV and pemphigus foliaceus 
(PF), and either Dsg 1 or Dsg 3 alone is sufficient to maintain keratino-
cyte adhesion in the upper and lower epidermal compartment, respec-
tively.8,9 The main postulate of the monopathogenic theory is that 
antibody- dependent disabling of Dsg 1- and/or Dsg 3- mediated cell–
cell attachment of KCs is sufficient to disrupt epidermal integrity and 
cause blistering.
2.1 | Summary of data supporting the 
monopathogenic theory (see Supplement for details)
The clinical and experimental data supporting the unique pathogenic 
role of anti- Dsg antibodies sufficient to explain the clinical  phenotype 
and lesion formation in the great majority of pemphigus patients 
include reports about the presence of antibodies against Dsg 3 and/
or Dsg 1 in 95% of pemphigus sera and correlation of antibody titres 
with disease activity and clinical phenotype, such as Dsg 1 in PF, Dsg 
3 in mucosal PV and Dsg 1+Dsg 3 in mucocutaneous PV;10,11 induc-
tion of PF- and PV- like lesions by Dsg 1 and Dsg 3 antibodies, respec-
tively, affinity purified from patients’ sera (Refs 12,13 and E. Schmidt, 
TABLE  1 Major controversies about pemphigus pathogenesis (modified from Ref. 58,69)*
Major postulates of the monopathogenic theory:
Findings counteracting the respective postulates of the 
 monopathogenic theory:
(i) Epidermal integrity primarily depends on the desmosomal 
expression of Dsg 1 and Dsg 3
vs (i) Epidermis in patients with PV who develop both Dsg 1 and 3 
antibodies would have disintegrated to a single cell suspension if the 
integrity of epidermis was based exclusively on Dsg 1 and 3
(ii) Sera of patients with PV contain pathogenic autoantibod-
ies targeting preferentially the Dsg 1/3 targets
vs (ii) The autoantibodies eluted from certain recombinant Dsg 1 and 
Dsg 3 protein constructed recognized non-specifically several 
non- Dsg keratinocyte proteins
(iii) Pemphigus acantholysis results from inactivation of Dsg 
1 and/or 3 molecules by corresponding autoantibodies due 
to steric hindrance and/or internalization
vs (iii) In addition to blocking function of adhesion molecules on 
keratinocyte cell membrane, PVIgG elicit pro- apoptotic signalling 
events causing cell shrinkage, detachment from neighbouring KCs and 
rounding up—the unique process of PVIgG- triggered signalling events 
collectively described by the term apoptolysis
(iv) PV phenotype can be reproduced in mice solely by 
genetically or antibody- mediated inactivation Dsg 3
vs (iv) Mice with genetically or antibody- mediated inactivation of Dsg 3 
develop some but not all clinical–histological manifestations of PV 
(that is, pseudo pemphigus phenotype)
(v) An interplay between Dsg 1 and 3 antibodies generally 
determines the mucocutaneous phenotype in PV and PF
vs (iv) The Dsg 1/3 antibody profile does not always match the predicted 
clinical phenotype based on the relative Dsg 1 and Dsg 3 expression 
pattern in skin and mucosa
(vi) Serum concentrations of anti- Dsg 1/3 IgG grossly 
correlate with the clinical activity of PV and PF
vs (vi) Serum concentrations of Dsg 1/3 antibodies do not always 
correlate with the clinical activity of PV and PF
*Abbreviations: KC, keratinocytes; PF, pemphigus foliaceus; PV, Pemphigus vulgaris.
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unpublished data); induction of PV- like lesions associated with des-
mosomal degradation and acantholysis by Dsg 3 antibodies in vitro 
and in Rag2- deficient mice with splenocytes from Dsg 3- deficient 
mice;14–21 induction of acantholysis in vitro/ex vivo by IgG from HLA- 
DRB1*04:02- transgenic mice immunized with human Dsg 3 or Dsg 
3 peptides;22 and abrogation of acantholytic activity of sera from 
patients with PF and PV due to depletion of anti- Dsg 1 and anti- Dsg 3 
reactivities, respectively.23–25 Indirect support is provided by reports 
that apoptosis is not required for the induction of desmosomal degra-
dation and acantholysis by PVIgG in vitro and that apoptotic cells are 
scarce and mostly absent in lesional skin of pemphigus patients.26–28 
Apoptotic events may arise in later stages of the disease after acan-
tholysis had occurred.26
2.2 | Summary of data challenging the 
monopathogenic theory (see Supplement for details)
Several clinical studies demonstrated lack or weak correlations of 
anti- Dsg reactivity with clinical phenotype. The Dsg 1/3 antibodies 
can be absent in patients with PV in active stage of disease but pre-
sent in patients with PV during remission as well as in healthy sub-
jects and patients with irrelevant medical conditions.1,4,12,29–47 In a 
number of studies, Dsg 3 antibody levels did not correspond to the 
presence of cell surface antibodies detectable by indirect immuno-
fluorescence or predict relapse of the disease.48–51 Furthermore, 
the Dsg 1/3 antibody pattern did not match the predicted mor-
phologic phenotype of pemphigus.1 4,6,13,40,46,52 Inactivation of the 
Dsg 1- or 3- mediated adhesion induces overt blistering—an indis-
pensible feature of pemphigus phenotype—in neither patients with 
DSG1 mutations 53,54 nor any hitherto described mouse models 
of Dsg 3 inactivation, through either genetic manipulations55–57 
or anti- Dsg 3 antibody production (reviewed in,58 as would be 
expected if inactivation of Dsg 1 and Dsg 3 was a sole cause of PF 
and mucosal PV, respectively. Notably, acantholysis per se does 
not constitute true pemphigus phenotype, because it can be seen 
in patients with a variety of dermatological conditions who do not 
develop blisters and erosions characteristic of pemphigus. On the 
other hand, despite the presence of functional Dsg 3, the Dsc3fl/fl/
K14- Cre mice lacking desmocollin (Dsc) 3 develop extensive skin 
blistering,59 indicating that Dsg 3 alone is not sufficient to main-
tain epidermal cohesion. Furthermore, it has been demonstrated 
that extracellular domain of Dsg 3 mediates only a weak homo-
philic adhesion in vitro60 and that inhibition of Dsg 3 binding is not 
sufficient to cause loss of cell cohesion.61 Therefore, not surpris-
ingly, human KCs deprived of endogenous production of Dsg 1 or 
3 due to gene silencing via RNAi continue to form desmosomes.62 
Noteworthily, results showing that chimeric proteins containing 
the extracellular epitope of Dsg 1 or 3 combined with the Fc por-
tion of human IgG1 absorbed out all disease- causing pemphigus 
IgGs 23,24,63 are interpreted with caution, because patients with 
PV produce autoantibodies against Fc- IgG2,
64 and PVIgG eluted 
from the Dsg/Fc- IgG chimeras react with multiple keratinocyte 
proteins.65,66
3  | THE MULTIPATHOGENIC THEORY OF 
PEMPHIGUS PATHOPHYSIOLOGY
The multipathogenic theory of pemphigus pathophysiology explains 
intra- epidermal blistering through the “multiple hit” hypothesis.67 
According to this hypothesis, a simultaneous and synchronized inac-
tivation of the physiological mechanisms regulating and/or mediating 
intercellular adhesion of KCs is necessary to disrupt their most impor-
tant phylogenetic function such as maintenance of epidermal integrity. 
Individual variations within the constellations of pathogenic PVIgG tar-
geting different keratinocyte proteins likely determine the magnitude 
of the “multiple hit” attack required to disrupt epidermal integrity in a 
particular patient with PV, and explain the clinical and immunopatho-
logical variability of PV. The term “pathogenic” is applicable to the 
non- Dsg antibodies that can induce one or more of the PV- relevant 
changes of KCs, such as cell shrinkage, cell–cell detachment and/or 
pro- apoptotic signalling. In addition, it has been documented that 
PVIgG synergize with the effectors of apoptotic and oncotic pathways, 
serine proteases and inflammatory cytokines to overcome the natu-
ral resistance and activate the cell death programme in KCs (Fig. 1). 
The major premise for the multipathogenic theory is the hypothesis 
that a single type of autoantibody induces only reversible changes, so 
that affected KCs can recover due to a self- repair. The damage, how-
ever, becomes irreversible when the salvage pathway and/or other 
cell functions are altered by a partnering autoantibody and/or another 
F IGURE  1 Hypothetical scheme of multipathogenic theory of 
pemphigus (modified from Ref. 81). The process of keratinocyte 
damage in PV is rather complex and relies upon a synergistic action of 
antibodies to adhesion molecules, mitochondrial proteins and other 
kinds of self- antigens, like acetylcholine receptors, as well as humoral 
factors, such as FasL, TNF- α, cytokines, serine proteases and nitric 
oxide, that by acting altogether become able to overcome the natural 
resistance and activate both the extrinsic and intrinsic cell death 
pathways in KCs. FcRn is an indispensible element of pathogenic 
action of antimitochondrial antibodies and, perhaps, other PVIgG 
species that target intracellular self- antigens. AMA, antimitochondrial 
antibodies; Cs, caspase; FasL, Fas ligand; FasR, Fas receptor; NO, 
nitric oxide; nDPVAb, other non- Dsg PV antibodies; OPVAg, other PV 
antigens; PVAb, PV antibody; TNF- α, tumor necrosis factor- α 
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pathogenic factor, for example Fas ligand (FasL). Thus, a simultaneous 
and synchronized inactivation of the several physiological mechanisms 
regulating and mediating intercellular adhesion of KCs is apparently 
required to irreversibly disable their most important phylogenetic 
function such as maintenance of epidermal integrity.
3.1 | Summary of data supporting the 
multipathogenic theory (see Supplement for details)
The first evidence that non- Dsg antibodies are pathogenic was provid-
ed in the study of Amagai et al.12 who demonstrated that gross blisters 
were induced in mouse skin by the PVIgG depleted of Dsg 3 antibody. 
Later on, neonatal Dsg 3−/− mice developed the PV phenotype featur-
ing widespread blistering only after passive transfer of PVIgG lacking 
anti- Dsg 1 antibody, indicating that blisters were induced by target-
ing the non- Dsg 1 and 3 antigens.68 Thus far, the published evidence 
directly or indirectly supporting the role for non- Dsg antibodies and 
other endogenous pathogenic factors in pemphigus pathophysiology 
include the differences between the pathobiological effects of Dsg 3 
antibody and the total PVIgG serum fraction at both the ultrastructural 
and biochemical levels, over forty different keratinocyte protein bands 
identified by immunoblotting and/or immunoprecipitation as “pemphi-
gus antigens” and direct pathogenic effects of non- Dsg antibodies on 
KCs (reviewed in Ref. 69) as well as involvement of apoptotic signalling 
events in pemphigus acantholysis providing a rationale of the concept 
of apoptolysis.70 In addition to Dsg 1 and 3 molecules, recent prot-
eomic analyses of large quantities of pemphigus and normal control 
sera47,71 revealed reactivities with Dsc 1 and 3, several muscarinic 
and nicotinic acetylcholine receptor subtypes, HLA molecules, a num-
ber of mitochondrial proteins and some other intracellular molecules 
including thyroid peroxidase and the Ca2+/Mn2+- ATPase, or hSPCA1, 
encoded by the ATP2C1 gene. The highest specificity to PV showed 
the combinations of autoantibodies to hSPCA1 with C5a receptor plus 
Dsc 1 or Dsc 3 or HLA- DRA.47 Indeed, anti- Dsc 3 PVIgGs have been 
shown to be pathogenic.72,73 Noteworthily, one copy of ATP2C1 is 
mutated in patients with Hailey–Hailey disease (a.k.a. familial benign 
chronic pemphigus) representing a non- immune phenocopy of cutane-
ous lesions in PV.74,75 Both Hailey–Hailey disease KCs76 and normal 
KCs treated with PVIgG77 exhibit altered intracellular calcium metabo-
lism that can lead to abnormal cell–cell adhesion.78 An expanded dis-
cussions of possible pathogenic roles of new pemphigus antibodies 
detected by in proteomics studies can be found elsewhere.47,64,71,79
Although the adhesion molecules targeted in PV may potentially 
induce downstream signalling events,80 the PVIgG- induced activa-
tion of epidermal growth factor receptor and Src was not affected in 
Dsg3−/− KCs.81 Src activation is an early acantholytic event82 triggered 
by non- Dsg PVIgG.62 In addition to activating the oncosis effector,83 
both extrinsic and intrinsic apoptotic signalling pathways are activated 
in KCs treated with PVIgGs,83,84 with the principal effector molecules 
being FasL84,85 and cytochrome c,81,86 respectively. Both acantholysis 
and apoptotic signalling can be triggered by the same signal effectors 
activated by PVIgG and mediated by the same set of cell death enzymes, 
because, on the one hand, inhibitors of Src, EGFRK, p38 MAPK and 
mTOR can block both acantholysis and apoptotic events,62,70,87–92 
and, on the other hand, caspase inhibitors can prevent acantholysis 
both in vitro and in vivo.83,90,93,94 Apoptotic enzymes can cleave Dsg 
1, 2 and 3,95–97 thus representing the principal effector of apoptol-
ysis—a unique paradigm of keratinocyte damage in PV that is non- 
synonymous with apoptosis.70 Antimitochondrial antibodies (AMA) 
target the mitochondrial nicotinic acetylcholine receptors that protect 
KCs from apoptolysis.98 Noteworthily, Dsg 3 does not serve as a surro-
gate antigen allowing AMA to enter KCs.81 The susceptibility of KCs to 
apoptolysis in PV may be increased due to the presence of a polymor-
phic variant of the ST18 gene encoding a pro- apoptotic molecule.99
4  | UNRESOLVED ISSUES
1. Little is known about the cutaneous inflammation which follows 
binding of PVIgG to KCs and may contribute to intra-epidermal 
loss of adhesion and blister formation. Local factors, such as innate 
immune mechanisms, may enhance a proinflammatory environment 
with an IL-1β-/TNF-α-dominated signature that facilitates blister 
formation presumably via production of IL-6.100,101 This contention 
is supported by previous findings that injection of pathogenic 
anti-Dsg antibodies into newborn mice did not result in intra-epi-
dermal loss of adhesion in mice deficient for IL-1 receptor 1, the 
receptor for the proinflammatory cytokines IL-1α and IL-1β;102
2. While intramolecular and intermolecular epitope spreading among 
extracellular domains on Dsg 1 and Dsg 3 is rare in PV and has no 
correlation with disease course,103 a possibility that epitope spread-
ing may play a role in generation of autoantibodies that target a 
variety of desmosomal autoantigens in PV needs to be explored;
3. The largely accepted critical role of autoreactive T-cell interaction 
with autoreactive memory B cells and the induction of pemphigus-
specific plasma cells is also not yet fully elucidated;104
4. The presence of IgA, IgM and IgE antibodies to KCs in some pem-
phigus patients105–107 suggests their direct pathogenic role with or 
without synergy with IgG autoantibodies and warrants future 
research in this unexplored direction.
5  | EVIDENCE OF SYNERGY OF ANTI-  DSG  
AND NON- DSG ANTIBODIES IN PEMPHIGUS
The synergy within the pool of pathogenic PVIgG may stem from 
functional cooperation of autoantibodies to proteins mediating either 
the same and/or separate biologic functions of KCs. For example, 
through the first scenario, simultaneous blockade of the Dsg and 
Dsc molecules mediating their heterophilic trans-interactions within 
the desmosome108 may distort epidermal integrity more efficiently, 
compared to interference with cis-interactions of single- type desmo-
somal proteins. Through the second scenario, simultaneous attack 
on molecules that regulate shape and motility of KCs, such as acetyl-
choline receptors,109 and molecules that mediate cell–cell adhesion, 
such as desmosomal cadherins, will inactivate the adhesive function 
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of desmosomal cadherins due to their phosphorylation and internali-
zation, leading to shrinkage of KCs,87 and prevent formation of new 
desmosomes due to steric hindrance at nascent desmosomes, respec-
tively. In other words, non- Dsg antibodies may potentially “amplify” 
the activity of anti- Dsg antibodies.
Direct evidence of synergy between anti- Dsg and non- Dsg anti-
bodies in PV is illustrated by complementary activities anti- Dsg 1/3 
and AMA in organ culture of neonatal mouse skin (OCNMS)—the high-
ly sensitive in vitro model of PV.110 Preabsorption of PVIgG with either 
non- mitochondrial or mitochondrial proteins in both cases prevent-
ed acantholysis, indicating that both AMA and non- AMA antibodies 
were indispensible for acantholysis.110 However, treatment of mouse 
skin only with AMA did not cause acantholysis. Herein, it should be 
clarified that despite the demonstrated ability of anti- Dsg 1/3 mono-
clonal antibodies to induce keratinocyte monolayer fragmentation in 
vitro and microscopic blisters in ex vivo model and in neonatal mice 
(reviewed in Ref. 111), there exists a possibility of non- physiological 
interference with desmosome formation and function due to appli-
cation of suprapharmacological doses of such anti-Dsg antibodies. In 
fact, recent experiments with OCNMS demonstrated that while high 
concentrations of the human anti- Dsg monoclonal PV antibody scFv 
could induce acantholysis on its own, its dilution down to ~0.16 μg/μL 
could not,110,112 which allowed to investigate its synergy with AMA. 
As expected, acantholysis was induced when AMA were added to the 
non- acantholytic dose of scFv.110 Likewise, acantholysis developed 
when AMA were combined with commercial anti- Dsg antibodies. The 
AMA/anti- Dsg 1 combination induced subcorneal splitting and AMA/
anti- Dsg 3—a suprabasal one, consistent with respective predominant 
localization of Dsg 1 and Dsg 3.9
In a separate study, a commercially available antithyroid peroxi-
dase antibody and the mouse monoclonal anti- Dsg 3 antibody AK23 
produced increased fragmentation in keratinocyte dissociation assays 
in vitro when used in combination, as compared to each individual 
antibody.113,114
Thus, the pathogenic role of non- Dsg antibodies is complemen-
tary, not alternative, to that of Dsg antibodies, and both anti- Dsg and 
non- Dsg types of autoantibodies appeared to be required to disrupt 
integrity of the epidermal barrier.
The multipathogenic theory also explains why KCs remain the only 
cell type affected by PV autoimmunity despite the fact that the major-
ity, if not all, PV autoantigens have been found in other cell types. 
Recent studies of the role of FcRn in the pathogenic action of AMA in 
PV have implicated KCs as a single target in pemphigus based on the 
fact that these cells have in place all essential elements of the cellular 
machinery implementing apoptolysis upon binding of PVIgG. Briefly, 
in keeping with the notion that FcRn (“neonatal” Fc receptor for IgG) 
can bind IgG on the cell membrane,115–119 it was demonstrated that 
PVIgG physically associates with FcRn on the cell membrane of KCs, 
following which the PVIgG- FcRn complexes become internalized, traf-
ficked through the cytosol to the mitochondria where the complexes 
are liberated from endosome and dissociate allowing AMA to dam-
age mitochondria, which triggers apoptotic signalling associated with 
cell shrinkage.110 Furthermore, while it had been known that FcRn 
deficiency caused by either its blockade with a neutralizing anti- FcRn 
antibody or gene knock- out in both cases interferes with the ability 
to induce phenotypes of humorally mediated autoimmune diseases in 
mice, including PV and PF,120–126 it has been recently demonstrated 
that AMA alter mitochondrial respiration only in those cell types that 
express FcRn.110 Lack of FcRn prevented both PVIgG internalization 
and its ability to reach mitochondria. Furthermore, functional inac-
tivation of FcRn due to pretreatment of KCs with mouse anti- FcRn 
antibody prevented AMA- dependent alterations of mitochondrial 
metabolism and integrity, as well as keratinocyte shrinkage.110
KCs with damaged mitochondria shrink because they run out of 
energy and because caspases activated due to cytochrome c release 
can cleave structural and adhesion molecules resulting in the cyto-
skeleton collapse.70 The AMA- induced damage, however, is revers-
ible.110 During recovery, when KCs extend their cytoplasmic aprons 
towards neighbouring cells, re- assembly of desmosomes is blocked 
by steric hindrance of anti- Dsg antibodies that leads to irreversible 
acantholysis, or apoptolysis. The fact that FcRn is predominant-
ly expressed within the basal epidermal layer127 may render basal 
KCs a preferred functional target for PVIgG to intracellular anti-
gens, thus explaining why they shrink more than suprabasal KCs,128 
despite the fact that both basal and suprabasal KCs are targeted 
by PVIgG.129 Thus, FcRn appears to be an indispensible element of 
the autoimmunity against intracellular antigens in KCs but not other 
cell types.
For example, although both breast and urinary bladder epithelial 
cells express Dsg 1 (http://www.proteinatlas.org/ENSG00000134760-
DSG1/tissue), they are not damaged in the Dsg 1 antibody- positive 
patients with PV. The synergy of Dsg 1 antibody and AMA in these 
cells apparently does not occur because neither cell type expresses 
FcRn.110 Additionally, an indirect evidence of important role of FcRn 
in PV is rendered by the facts that an excess of normal IgG that can 
saturate FcRn protects KCs from PVIgG- induced apoptolysis in vitro,83 
and that high- dose IVIg is therapeutic in patients with PV (reviewed 
in Ref. 130). Thus, it is becoming increasingly evident that an array 
of interconnected signalling cascades emanating from different cell 
surface and intracellular proteins simultaneously targeted by genetic 
abnormalities, such as the ST18 SNP, pathogenic antibodies and some 
other endogenous pathogenic factors contribute to the evolving pem-
phigus phenotype.
6  | KEY POINTS
1. Epidermal acantholysis resulting from null mutation of DSG1 in 
patients with SAM syndrome or in mice with null mutation of 
Dsg3 or Rag2−/− mice producing anti-Dsg 3 antibodies does not 
cause gross blistering, indicating that neither anti-Dsg 1 nor 
anti-Dsg 3 antibodies can be solely responsible for blistering in 
patients with PF and PV, respectively.
2. Reports about the presence and pathogenic relevance of a non-Dsg 
antibodies are accumulating and have questioned the monopatho-
genic theory. The presence of multiple autoantigen–autoantibody 
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systems in PV and interpatient variations may explain, in part, 
known problems with reproducibility of certain results. Therefore, 
future studies are needed to (i) corroborate these findings, (ii) char-
acterize in detail patient populations with non-Dsg-specific autoan-
tibodies, and (iii) determine the extent of the contribution of 
non-Dsg PVIgG in disease pathophysiology.
3. Patients with PV develop antibodies against multiple organ-spe-
cific and non-organ-specific proteins, some of which are also tar-
geted in other types of autoimmune diseases. Both anti-Dsg and 
non-Dsg antibodies are pathogenic in a sense that they are ele-
ments of the multifactorial pathophysiological mechanism of PV. 
Various PVIgG species may concur to cause blistering by acting 
synergistically. The preferential signalling pathway downstream 
of targeted self-antigens is apparently determined by a unique 
composition of the pool of antikeratinocyte antibodies produced 
by each patient with PV. Distinct constellations of autoantibod-
ies developed by different patients with PV determine clinical 
severity of the disease, its natural course and response to 
treatment.
4. The mechanism of pemphigus apoptolysis encompasses several 
tiers of events triggered through distinct signalling pathways, 
including genetic predisposition to production of antikeratinocyte 
antibodies and increased sensitivity of KCs to the tissue and serum 
factors that trigger extrinsic and/or intrinsic apoptotic pathways. 
Thus, during apoptolysis, KCs become both a target and a source of 
various inflammatory and pro-apoptotic factors. Understanding of 
PV pathophysiology, however, is still incomplete, because the ancil-
lary pathways triggered by pathogenic antibodies and other patho-
genic factors remain largely unknown.
5. Although there are no known clinical and pathological differences 
between PV patients with vs without anti-Dsg antibodies, the 
immunopathology may be different. The growing evidence about 
acantholytic activities of non-Dsg antibodies in PV urges mechanis-
tic studies of keratinocyte damage in the anti-Dsg antibody-nega-
tive patients with PV. Therefore, IgGs from the sera of patients 
with PV, who developed mucocutaneous blisters in the absence of 
anti-Dsg1/3 antibodies, provide a unique experimental tool to elu-
cidate novel aspects of PV pathophysiology.
6. Although multiple hits sustained by a constellation of autoantibod-
ies seem to be required to breach epidermal integrity, elimination 
of or pharmacological protection from a single type of pathogenic 
antibody may suffice to abort development of the disease. 
Therefore, elucidation of the repertoire of pathogenic antibodies in 
individual patients will further improve our understanding of immu-
nopathogenesis of their disease.
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